• Junzo Kigawa
  • Tsunehisa Kaku
  • Toru Sugiyama
  • Steven G. Silverberg


The immunohistochemical features of ovarian clear cell carcinoma (CCC) have only been described in small series of cases, and our own large series has not been the object of extensive immunohistochemical study. As an epithelial carcinoma, CCC reacts with most markers of epithelial differentiation, but relatively few more specific markers of clear cell differentiation are available. Two of these which are said to be positive in most but not all cases are HNF-1 beta (hepatocyte nuclear factor-1 beta) and ARID1A. Generally negative immunostains in CCC which may be of differential diagnostic value include WT-1, estrogen (ER) and progesterone (PR) receptors, and p53.


Progesterone Receptor Clear Cell Carcinoma Mucinous Carcinoma Serous Carcinoma Endometrioid Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kobel M, Bak J, Bertelsen BI, Carpen O et al (2014) Ovarian carcinoma histotype determination if highly reproducible, and is improved through the use of immunohistochemistry. Histopathology 64:1004–1013. doi: 10.1111/his 12349 CrossRefPubMedGoogle Scholar
  2. 2.
    DeLair D, Oliva E, Kobel M, Macias A et al (2011) Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol 35:36–44CrossRefPubMedGoogle Scholar
  3. 3.
    Tsuchiya A, Sakamoto M, Yasuda J, Chuma M et al (2003) Expression profiling in ovarian clear cell carcinoma: identification of hapatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163:2503–2512CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Acs G, Pasha T, Zhang PJ (2004) WT1 is differentially expressed in serous, endometrioid, clear cell, and mutinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 23:110–118CrossRefPubMedGoogle Scholar
  5. 5.
    Sieh W, Kobel M, Longacre TA, Bowtell DD et al (2013) Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 14:853–862CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Itamochi H, Kigawa J, Sugiyama T et al (2002) Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100:281–287CrossRefPubMedGoogle Scholar
  7. 7.
    Oishi T, Itamochi H, Kigawa J et al (2007) Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer 17:1040–1046CrossRefPubMedGoogle Scholar
  8. 8.
    Sekiya R, Kajiyama H, Sakai K et al (2012) Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary. Hum Pathol 43:904–910CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2015

Authors and Affiliations

  • Junzo Kigawa
    • 1
  • Tsunehisa Kaku
    • 2
  • Toru Sugiyama
    • 3
  • Steven G. Silverberg
    • 4
  1. 1.Matsue City HospitalMatsueJapan
  2. 2.Department of Health SciencesDepartment of Health Sciences Graduate School of Medical SciencesFukuokaJapan
  3. 3.Department of Obstetrics and GynecologyIwate Medical University School of MedicineMoriokaJapan
  4. 4.Department of PathologyUniversity of Maryland School of MedicineBaltimoreUSA

Personalised recommendations